ALPHATEC HOLDINGS INC

Alphatec insiders buy shares, signaling confidence in its spine‑surgery growth and a potential turnaround driven by new incentive plans and value‑based reimbursement.

Alphatec’s insider buys signal confidence as the company’s ALPHA™ spinal implants hit 92% fusion rates and FDA‑cleared, with the upcoming ALPHA™ Plus launch poised to drive future earnings and mitigate dilution risks.

Alphatec insiders sell large blocks amid a 37% fall—discover why EVP David Sponsel’s $13.79 sale matters for investors and future outlook.

Alphatec insider selling shows routine portfolio moves, not a warning—learn why executives trade, how it impacts stock and future spine‑surgery prospects.